CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Contineum Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$7.44+0.36 (+5.08%)

Close on Oct 19, 2026

Market cap: $278.76M
P/E (TTM): –
Dividend yield: –

Contineum Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31
Cash & Equivalents	15	20	76	43	21	22	22	41	77	16	16	–	–	–	–
Short-Term Investments	222	226	187	140	155	168	183	173	141	102	110	–	–	–	–
Cash & Short-Term Investments	237	246	263	182	176	191	205	214	219	118	125	–	–	–	–
Prepaid Expenses & Other	6.03	6.64	5.02	2.52	1.36	1.42	1.63	1.23	1.67	1.80	2.52	–	–	–	–
Total Current Assets	243	253	268	185	177	192	206	215	220	120	128	–	–	–	–
Property, Plant & Equipment	0.93	1.06	0.83	0.88	0.86	0.89	0.99	0.89	0.80	0.76	0.68	–	–	–	–
Gross Property, Plant & Equipment	–	–	2.79	–	–	–	2.71	–	–	–	2.16	–	–	–	–
Accumulated Depreciation	–	–	-1.96	–	–	–	-1.72	–	–	–	-1.48	–	–	–	–
Operating Lease Right-of-Use Assets	6.49	7.02	7.64	4.77	5.01	5.24	5.47	5.60	0.23	0.47	0.72	–	–	–	–
Other Long-Term Assets	0.36	0.31	0.26	0.27	0.19	0.00	0.00	0.00	0.00	2.62	1.28	–	–	–	–
Total Assets	250	261	277	191	183	198	213	216	221	124	130	–	–	–	–
Accounts Payable	0.51	1.50	1.02	0.79	2.00	3.65	1.81	1.40	0.73	0.57	0.64	–	–	–	–
Accrued Expenses	3.63	2.86	6.39	4.10	3.75	3.85	6.71	3.80	2.52	5.19	4.39	–	–	–	–
Current Portion of Leases	2.39	2.30	2.34	1.48	1.47	1.46	1.45	0.61	0.48	0.47	0.46	–	–	–	–
Total Current Liabilities	6.53	6.66	9.74	6.36	7.21	8.95	9.97	5.81	3.74	6.23	5.48	–	–	–	–
Long-Term Leases	4.18	4.65	5.91	4.02	4.28	4.55	4.81	0	0.11	0.11	0.11	–	–	–	–
Operating Lease Liabilities	6.57	6.95	8.25	5.49	5.75	6.00	6.26	5.60	0.60	0.59	0.57	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	–	0	0	0	0.23	0.11	–	–	–	–
Total Liabilities	11	11	16	10	11	13	15	5.81	3.85	6.57	5.70	–	–	–	–
Preferred Stock	0	0	0	0	0	0	0	0	0	–	0	–	–	–	–
Common Stock	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–	–	–
Additional Paid-In Capital	447	442	438	342	321	318	315	312	310	7.99	7.10	–	–	–	–
Retained Earnings	-207	-192	-177	-162	-149	-133	-117	-103	-93	-84	-75	–	–	–	–
Comprehensive Income & Other	-0.57	-0.25	0.26	0.27	0.15	0.17	0.07	0.56	-0.13	-0.06	0.11	–	–	–	–
Shareholders' Equity	240	250	261	180	171	185	198	210	218	-76	-68	-61	-55	-97	-93
Total Equity	240	250	261	180	171	185	198	210	218	-76	-68	-61	-55	-97	-93
Total Liabilities & Equity	250	261	277	191	183	198	213	216	221	124	130	–	–	–	–
Shares Outstanding(shares)	–	–	–	–	–	–	–	–	–	2.38	2.35	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -26.1%

Financial strength

Current ratio: 37.17
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 225.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.16
Dividend yield: –